Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRA

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

- PMLiVE

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

- PMLiVE

Brexit – a tough pill to swallow

What will be expected of the UK when the post-Brexit environment takes shape?

- PMLiVE

Kite bags $90m upfront in two Asian deals for lead CAR-T drug

Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma

- PMLiVE

Takeda agrees $5.2bn deal to buy Ariad

Acquires cancer firm in the first big pharma M&A deal of 2017

Bristol-Myers Squibb (BMS) building

BMS restructures US R&D operations

Unveils site closures and build plans as firm focuses pipeline around three US hubs

- PMLiVE

Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands

dengue fever mosquito

Takeda plans German plant to support dengue vaccine roll-out

Will invest more than €100m in the Singen manufacturing facility

- PMLiVE

Takeda gets EU green light for oral myeloma drug

Ninlaro first oral proteasome inhibitor to be registered in Europe

- PMLiVE

Shire to focus rare disease R&D with new US facility

Cambridge, Massachusetts hub to drive firm’s push to become leading rare disease specialist

- PMLiVE

Another late-stage setback tarnishes Gilead’s R&D lustre

Myelofibrosis drug candidate fails to best Incyte/Novartis’ Jakafi in phase III trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links